Cost-Utility Analysis of Community Case Management for Malaria Control in Burundi

Document Type : Original Article


1 Social, Economic and Administrative Pharmacy Program, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand

2 Division of Social and Administrative Pharmacy, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand


The community case management (CCM) program for malaria control is a community-based strategy implemented to regulate malaria in children in Burundi. This study compared the cost and utility of implementing the CCM program combined with health facility management (HFM) versus HFM alone for malaria control in children under five in Burundi.

This study constructed a five-year Markov model with one-week cycles to estimate cost-utility and budget impact analysis (BIA). The model defined 10 health states, simulating the progression of the disease and the risk of recurrent malaria in children under five years of age. Cost data were empirically collected and presented for 2019. Incremental cost per disability-adjusted life year (DALY) averted, and a five-year budget was estimated. One-way and probabilistic sensitivity analyses (PSAs) were then performed.

From provider and societal perspectives, combining the CCM program with HFM for malaria control in Burundi was more cost-effective than implementing HFM alone. The addition of CCM, using artesunate amodiaquine (ASAQ) as the first-line treatment, increased by US$1.70, and US$ 1.67 per DALY averted from the provider and societal perspectives, respectively. Using Artemether Lumefantrine (AL) as the first-line treatment, adding the CCM program to HFM increased by US$ 1.92, and US$ 1.87 per DALY averted from the provider and societal perspectives. At a willingness-to-pay of one GDP/capita, the CCM program remained a 100% chance of being cost-effective. In addition, implementing the program for five years requires a budget of US$ 15 800 486–19 765 117.

Implementing the CCM program and HFM is value for money for malaria control in Burundi. The findings can support decision-makers in Burundi in deciding on resource allocation, especially during the program’s scale up.


  1. Demographic and Health Surveys Program. Troisième Enquête Démographique et de Santé au Burundi (EDSB-III) 2016-2017 (Third demographic and health survey in Burundi 2016–2017). Institut de Statistiques et d’Études Économiques du Burundi; 2017.
  2. Moise IK. Causes of morbidity and mortality among neonates and children in post-conflict Burundi: a cross-sectional retrospective study. Children (Basel). 2018;5(9):125. doi:3390/children5090125
  3. Burundi Malaria Operational Plan FY 2018. USAID website. Accessed June 15, 2019. Published 2017.
  4. Lok P, Dijk S. Malaria outbreak in Burundi reaches epidemic levels with 5.7 million infected this year. BMJ. 2019;366:l5104. doi:1136/bmj.l5104
  5. Burundi GDP per capita. World bank website. Accessed June 15, 2019.
  6. Burundi Demographics. Worldmeter website. Accessed June 15, 2019.
  7. Kager PA. Malaria control: constraints and opportunities. Trop Med Int Health. 2002;7(12):1042-1046. doi:1046/j.1365-3156.2002.00981.x
  8. Sibomana S, Reveillon M. Improving Health System Efficiency: Burundi: Performance Based Financing of Priority Health Services. World Health Organization; 2015.
  9. World Health Organization (WHO). Scaling Up Home-Based Management of Malaria: From Research to Implementation. WHO; 2004.
  10. Case Study: Evaluation and Expansion of Community Case Management of Malaria to Support Informed Decision Making. USAID; 2016.
  11. Evaluation of Community Case Management of Malaria in the Pilot Health Districts of Ghombo, Gashoho, and Mabayi. USAID; 2018.
  12. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13(4):397-409. doi:2165/00019053-199813040-00003
  13. Lubell Y, Mills AJ, Whitty CJ, Staedke SG. An economic evaluation of home management of malaria in Uganda: an interactive Markov model. PLoS One. 2010;5(8):e12439. doi:1371/journal.pone.0012439
  14. Pfeil J, Borrmann S, Tozan Y. Dihydroartemisinin-piperaquine vs. artemether-lumefantrine for first-line treatment of uncomplicated malaria in African children: a cost-effectiveness analysis. PLoS One. 2014;9(4):e95681. doi:1371/journal.pone.0095681
  15. USAID: BURUNDI Malaria Operational Plan FY 2017. USAID website. Accessed June 15, 2019. Published 2017.
  16. Havyarimana C, Makuraza F, Nyandwi J, Manirakiza M, Muneza F, Nkengurutse D. Evaluation of the regulation of antibiotics consumption in Bujumbura, Burundi. J Pharm Pharmacol. 2017;5(10):760-765. doi:17265/2328-2150/2017.010.009
  17. Mori AT, Ngalesoni F, Norheim OF, Robberstad B. Cost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania. Malar J. 2014;13:363. doi:1186/1475-2875-13-363
  18. Seo MK, Baker P, Ngo KN. Cost-effectiveness analysis of vaccinating children in Malawi with RTS, S vaccines in comparison with long-lasting insecticide-treated nets. Malar J. 2014;13:66. doi:1186/1475-2875-13-66
  19. Gething PW, Kirui VC, Alegana VA, Okiro EA, Noor AM, Snow RW. Estimating the number of paediatric fevers associated with malaria infection presenting to Africa's public health sector in 2007. PLoS Med. 2010;7(7):e1000301. doi:1371/journal.pmed.1000301
  20. Lubell Y, Dondorp A, Guérin PJ, et al. Artemisinin resistance--modelling the potential human and economic costs. Malar J. 2014;13:452. doi:1186/1475-2875-13-452
  21. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376(9753):1647-1657. doi:1016/s0140-6736(10)61924-1
  22. Lubell Y, Staedke SG, Greenwood BM, et al. Likely health outcomes for untreated acute febrile illness in the tropics in decision and economic models; a Delphi survey. PLoS One. 2011;6(2):e17439. doi:1371/journal.pone.0017439
  23. Uzochukwu BS, Obikeze EN, Onwujekwe OE, Onoka CA, Griffiths UK. Cost-effectiveness analysis of rapid diagnostic test, microscopy and syndromic approach in the diagnosis of malaria in Nigeria: implications for scaling-up deployment of ACT. Malar J. 2009;8:265. doi:1186/1475-2875-8-265
  24. Lubell Y, Reyburn H, Mbakilwa H, et al. The impact of response to the results of diagnostic tests for malaria: cost-benefit analysis. BMJ. 2008;336(7637):202-205. doi:1136/bmj.39395.696065.47
  25. Four Artemisinin-Based Combinations (4ABC) Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med. 2011;8(11):e1001119. doi:1371/journal.pmed.1001119
  26. Shillcutt S, Morel C, Goodman C, et al. Cost-effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy. Bull World Health Organ. 2008;86(2):101-110. doi:2471/blt.07.042259
  27. Li B, Sun Z, Li X, et al. Performance of pfHRP2 versus pLDH antigen rapid diagnostic tests for the detection of Plasmodium falciparum: a systematic review and meta-analysis. Arch Med Sci. 2017;13(3):541-549. doi:5114/aoms.2017.67279
  28. Tables of Costs and Prices used in WHO-CHOICE Analysis. World Health Organization website. Updated 2010. Accessed June 15, 2019.
  29. World Health Organization. International Medical Products Price Guide. WHO; 2015.
  30. Ayieko P, Akumu AO, Griffiths UK, English M. The economic burden of inpatient paediatric care in Kenya: household and provider costs for treatment of pneumonia, malaria and meningitis. Cost Eff Resour Alloc. 2009;7:3. doi:1186/1478-7547-7-3
  31. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 2005.
  32. Official exchange rate (LCU per US$, period average) 2019. World Bank Accessed February 20, 2020.
  33. World Health Organization (WHO). World Health Statistics 2012: Life Tables for WHO Member States. Geneva: WHO; 2012.
  34. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2129-2143. doi:1016/s0140-6736(12)61680-8
  35. Edejer TT, Baltussen R, Tan-Torres T, et al. Making Choices in Health: WHO Guide to Cost-effectiveness Analysis. Geneva: World Health Organization; 2003.
  36. Country Implementation Profile 2012. UNFPA website. Accessed August 25, 2021.
  37. Escribano Ferrer B, Hansen KS, Gyapong M, et al. Cost-effectiveness analysis of the national implementation of integrated community case management and community-based health planning and services in Ghana for the treatment of malaria, diarrhoea and pneumonia. Malar J. 2017;16(1):277. doi:1186/s12936-017-1906-9
  38. Nonvignon J, Chinbuah MA, Gyapong M, et al. Is home management of fevers a cost-effective way of reducing under-five mortality in Africa? The case of a rural Ghanaian district. Trop Med Int Health. 2012;17(8):951-957. doi:1111/j.1365-3156.2012.03018.x
  39. Chanda P, Hamainza B, Moonga HB, Chalwe V, Banda P, Pagnoni F. Relative costs and effectiveness of treating uncomplicated malaria in two rural districts in Zambia: implications for nationwide scale-up of home-based management. Malar J. 2011;10:159. doi:1186/1475-2875-10-159
  40. Gadalla NB, Tavera G, Mu J, et al. Prevalence of Plasmodium falciparum anti-malarial resistance-associated polymorphisms in pfcrt, pfmdr1 and pfnhe1 in Muheza, Tanzania, prior to introduction of artemisinin combination therapy. Malar J. 2015;14:129. doi:1186/s12936-015-0642-2
  41. Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929-935. doi:1016/j.jval.2016.02.017
  42. Budget Brief: The 2017 Health Sector Budget. BURUNDI 2017. UNICEF website. Accessed February 20, 2020.
  43. Odikamnoro OO, Ikeh IM, Okoh FN, et al. Incidence of malaria/typhoid co-infection among adult population in Unwana community, Afikpo north local government area, Ebonyi state, Southeastern Nigeria. Afr J Infect Dis. 2018;12(1):33-38. doi:21010/ajid.v12i1.6

Articles in Press, Corrected Proof
Available Online from 11 May 2022
  • Receive Date: 28 April 2021
  • Revise Date: 07 May 2022
  • Accept Date: 10 May 2022
  • First Publish Date: 11 May 2022